.After antibody-drug conjugate (ADC) expert Seagen was offered to Pfizer in 2013 for a massive $43 b...
.On the heels of a phase 3 gain that failed to wow capitalists, Ironwood Pharmaceuticals is actually...
.Don't quit Monte Rosa Rehabs right now. The Boston-based biotech is enjoying after authorizing a ma...
.Accept to today's Chutes & Ladders, our summary of significant management hirings, shootings as ...
.Commemorating his company's upsized going public (IPO), Septerna CEO Jeffrey Finer rang the positio...
.AbbVie has come back to the source of its own antipsychotic giant Vraylar seeking one more runaway ...
.GenSight Biologics is actually full weeks far from running out of loan. Once more. The biotech mere...
.Monopar Rehabs is bouncing back a medication coming from the scrap heap of AstraZeneca's rare illne...
.Along with new data out on Arcus Biosciences' speculative HIF-2a inhibitor, one group of analysts w...
.After developing a genetics treatment alliance along with Dyno Therapies in 2020, Roche is actually...